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Background: The effects of obesity in combination with chronic obstructive pulmonary disease
(COPD) on exercise capacity are receiving increased attention. But, a comprehensive analysis
of factors associated with aerobic capacity in obese COPD patients has not been performed.
Methods: Six-min walking test (6MWT) was performed in 251 COPD patients, and 159 of those
also carried out an incremental cardiopulmonary exercise test (CPET) to evaluate exercise ca-
pacity. In all patients, anthropometrics, dyspnea and anxietyedepression scores, lung func-
tion, daily physical activity, co-morbidities and circulating inflammatory biomarkers were
also assessed. Six-min walking distance (6MWD) and peak oxygen uptake (VO2 peak) during
CPET were two primary outcome variables.
Results: 57% of the patients showed body mass index (BMI) < 30 kg/m2 (COPDN) and the re-
maining 43% were obese with a BMI  30 kg/m2 (COPDO). In patients with COPDN, 6MWD showed
independent negative associations with age, dyspnea score, sedentarism, depression scores
and a positive relationship with arterial oxygenation; whereas in COPDO, 6MWD showed an in-
verse relationship with BMI. In COPDN, VO2 peak showed a negative association with age and
positive relationships with both FEV1 and DLCO. However, in COPDO the dyspnea score was
the strongest determinant of VO2 peak.
Conclusions: Obese and non-obese COPD patients show different determinants of aerobic ca-
pacity, including pulmonary and non-pulmonary factors that are also dependent on the type of
exercise protocol. These results could be considered in the evaluation of obese patients with
COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Impaired exercise capacity is a cardinal feature of chronic
obstructive pulmonary disease (COPD) because it is asso-
ciated with poorer quality of life [1,2], increased use of
healthcare resources [2e4] and worse prognosis [5e7]. The
six-minute walking test (6MWT) [8] and the incremental
cardiopulmonary exercise (CPET) [9] are well accepted
tests to evaluate exercise capacity in COPD (10e12). Yet,
neither peak oxygen uptake (VO2 peak) determined during
CPET [10e12] or the six-minute walking distance (6MWD)
can be adequately predicted from the degree of airflow
limitation [13e15] as an isolated factor, indicating that
factors other than lung function impairment also modulate
exercise capacity in COPD. Obesity [16] is often associated
with COPD and it has the potential to contribute to exercise
limitation [17,18], but its individual contribution to
impaired aerobic capacity in these patients is unclear
[18e21]. Different studies seem to indicate that obesity
does not constitute a disadvantage during cycling exercise
in COPD patients [18,21]. In contrast, Bautista et al. [22]
reported that obese COPD patients had reduced 6MWD as
compared with those with normal body weight. However,
the mechanisms for the poorer walking performance in the
obese COPD group were not fully established [23].
We hypothesized that the contribution of resting lung
function, body composition and systemic inflammation to
exercise capacity in COPD differs according to the obesity
status. To test this hypothesis, we studied exercise capac-
ity, as assessed by both 6MWT and CPET, in 251 clinically
stable COPD patients with a wide range of airflow limitation
severity included in the PAC-COPD cohort, a multi-center
study conducted in 9 tertiary hospitals in Spain, some of
whose results have already been reported elsewhere
[20,24].Methods
Patients
A total of 342 COPD patients were consecutively recruited
from January 2004 to March 2006 during their first hospital
admission for COPD exacerbation in 9 tertiary hospitals
in Spain. The diagnosis of COPD was confirmed by forced
spirometry after discharge,when the patientwas considered
clinically stable. The severity of airflow limitationwas graded
according to European Respiratory Society and the American
Thoracic Society (ERS/ATS) criteria [25]. For the present
study, we excluded 42 patients withmissing data on exercise
capacity or body composition. Additionally, and because the
study focused on obese and normal weighted COPD patients,
wealso excludedpatientswith lowFat FreeMass Index (FFMI)
[26] (men < 17 kg/m2 and women < 14 kg/m2) (n Z 47).
Finally, two patients presenting simultaneously obesity and
low FFMI they were also excluded from the study, giving a
total of 251 subjects for the present analysis. There were no
significant differences on main clinical and functional char-
acteristics between included and excluded patients, except
for BMI. The study protocol was approved by the Ethics
Committees of the participating hospitals and written
informed consent was obtained from all subjects. Detailed
information on subject’s recruitment has been reported
elsewhere [20,24,27].Measurements
Patients were clinically stable for at least 6 weeks before
the study and all of them were under optimal medical
therapy. Exercise capacity was assessed by means of (i) the
six-minute walking test (6MWT) following ATS guidelines
Exercise in obese COPD patients 747[8] and (ii) incremental Cardiopulmonary Exercise Testing
(CPET) using an electromagnetically braked cycle-
ergometer and following international guidelines [9].
Body mass index (kg/m2) was computed from weight and
height in a physical examination, and composition was
assessed using bio-impedance to obtain FFMI. Patients were
classified in: obese COPD patients (body mass index,
BMI  30 kg/m2) (COPDO) and patients with BMI < 30 and
normal FFMI (COPDN) [26].
Laboratory lung function tests at rest, maximal inspira-
tory and expiratory pressures; peripheral muscle strength
and several serum inflammatory biomarkers (Tumor Necrosis
Factor [TNF] a, interleukin [IL]-6, IL-8, IL-10 and C-reactive
protein [CRP]) in the blood were assessed at the same time
during clinical stability. All patients answered an epidemio-
logical questionnaire assessing among other variables:
physical activity [using the Yale physical activity survey as
validated in Spanish for COPD patients [28]], health related
quality of life dyspnea [using the Modified Medical Research
Council (MMRC) scale [29]], andanxiety anddepression (HAD)
scale [30]. Co-morbidities were evaluated by Charlson Index.
Detailed information on measurements and procedures of
the PAC-COPD study has been reported elsewhere [20,24].
Data analysis
The results are expressed asmean (SD),median (P25eP75) or
number (percentages, %). Statistical analyses were done
using SPSS package v. 14. Differences between groups were
assessed by Differences between groups were assessed by
Chi-square test and unpaired t-test or Mann-Whitney U-test
(for quantitative variables with normal and non-normal dis-
tributions, respectively) and Chi-squared or Fisher’s exact
test (for qualitative variables).
As both 6MWD and VO2 peak were normally distributed,
multivariate linear regression models were used to identify
their determinants. Separate models were built for 6MWD and
VO2 peak. Potential determinants of 6MWD and VO2 peak
(mMRC dyspnea scale, BMI, FFMI, HAD depression scale, HAD
anxiety scale, physical activity, SGRQ scores, severity of
airflow limitation (FEV1), gas trapping (inspiratory to total lung
capacity), pulmonary diffusion impairment (DLco), arterial
oxygenation (PaO2), muscle force [handgrip, maximal inspi-
ratory and expiratory pressures (MIP and MEP)], serum in-
flammatory markers (TNF-a, CRP, IL-6, IL-8, IL-10) and co-
morbidities) as well as potential confounders of these associ-
ations (smoking status, gender, age) were tested in the
multivariate models and finally included in the final models if
(i) related to both the exposure and the outcome, or (ii)
modified (>10%change in regressioncoefficient) theestimates
of the remaining variables. Goodness of fit was assessed by
means of normality of residuals, heteroscedasticity, linearity,
collinearity and identification of influential data. The non-
standardized ß coefficient (ß coeff.) and its 95% confidence
interval of each covariate is reported to assess its relative in-
dependent effect on the outcome variable. All variables are
reported as continuous variables except physical activity
(Low<3000 kcal/week versus Normal 3000 kcal/week) [31].
To assess whether the determinants of exercise capacity are
different depending on obesity status, final linear regression
models were stratified according to COPDN and COPDO. A p-
value lower than 0.05 was considered statistically significant.Results
Table 1 displays the main characteristics of the two groups
of COPD patients by body composition. Overall, 57% of the
patients showed a BMI below 30 kg/m2 (COPDN, n Z 143)
and 43% of them were obese (COPDO, n Z 108). The anal-
ysis of resting lung function testing showed that forced
respiratory volume during first second (FEV1), Carbon
monoxide lung transfer capacity (DLco), maximal inspira-
tory pressure (MIP) and inspiratory to total lung capacity
ratio (IC/TLC) were higher in the COPDO group than the
COPDN patients, but no differences were observed in other
lung function variables or handgrip strength (Table 1).
Serum concentrations of the different inflammatory bio-
markers measured in the study were not different between
groups, except for IL-6 (Table 1).
Exercise capacity
6MWD was higher in COPDN compared to COPDO (Table 1).
Of note, however, VO2 peak (%predicted) and VE max were
similar in two groups. In contrast, workload, oxygen pulse
and the intensity of leg discomfort at peak exercise were
higher in COPDO (Table 1). Also COPDO showed a lower VE
peak/MVV ratio at peak of exercise than COPDN. Likewise,
both groups displayed similar cardiovascular response at
peak exercise, as assessed by heart rate and heart rate
reserve (p Z 0.729) (Table 1). We did not observe signifi-
cant differences on the reason for stopping (ie, breath-
lessness and/or leg fatigue) during incremental exercise
test between groups (p Z 0.387).
Determinants of exercise capacity by body
composition
Table 2 presents the multiple regression analysis results.
Age and dyspnea scores were inversely associated with
6MWD both in COPDN and COPDO. It is of note that dyspnea
showed a stronger association with 6MWD in COPDO than in
COPDN. By contrast, BMI was inversely associated with
6MWD only in COPDO. Walking distance in COPDN, in addi-
tion to age and dyspnea score mentioned above, also
showed a negative association with depression score and
positive relationships with both daily physical activity and
arterial oxygenation. With respect to VO2 peak, we found
that it was related inversely with age and positively asso-
ciated with FEV1 both in COPDN and COPDO.
The most relevant characteristic of COPDO was the
extremely high negative association between dyspnea score
and VO2 peak, not seen in COPDN, which accounted for a
large proportion of the variance explained by the equation.
Systemic inflammatory markers and respiratory and hand-
grip muscle force were not related to exercise capacity in
this study group.
Discussion
The results of the study indicate that: (1) COPDO showed
distinctive determinants of exercise capacity compared
to COPDN; (2) Dyspnea, was a stronger predictor of ex-
ercise capacity in COPDO than in COPDN, irrespective of
Table 1 Characteristics of the subjects by body composition.
Clinical and functional variables COPDN
n Z 143
COPDO
n Z 108
p-Valuea
Sex: male, n (%) 142 (99) 102 (95) 0.087
Age (yr) 67 (8) 68 (8) 0.948
Active smokers, n (%) 85 (59) 58 (54) 0.444
Body mass index (kg/m2) 26.2 (2.2) 33.2 (2.8) <0.001
Fat free mass index (kg/m2) 19.4 (1.6) 22.0 (2.7) <0.001
Dyspnea (mMRC scale) 2.0 (2e3) 2.5 (2e3) 0.312
Anxiety (HAD scale) 5.0 (1e8) 4.0 (1e7) 0.054
Depression (HAD scale) 3.0 (1e5) 3.0 (1e5) 0.969
Physical activity (kcal/week), median (P25eP75) 5373 (3243e8939) 6539 (3245e10,147) 0.247
FEV1 (L) 1.5 (0.5) 1.7 (0.4) <0.001
FEV1 (%predicted) 49 (16) 58 (8) <0.001
DLCO (% predicted) 63 (20) 72 (20) 0.002
Total lung capacity (% predicted) 103 (19) 94 (17) <0.001
Inspiratory to total lung capacity 0.29 (0.09) 0.35 (0.08) <0.001
PaO2 (mmHg) 75 (11) 73 (10) 0.197
MIP (% predicted) 66 (25) 59 (21) 0.029
MEP (% predicted) 64 (22) 65 (22) 0.598
Handgrip dominant (kg) 32 (7) 34 (8) 0.234
TNF a (pg/dl) 0.18 (0e0.9) 0.04 (0e0.5) 0.335
CRP (mg/dl) 0.34 (0.1e0.9) 0.40 (0.2e0.7) 0.094
IL-6 (pg/ml) 0.90 (0.4e1) 1.18 (0.6e2.0) 0.020
IL-8 (pg/ml) 4.19 (3.1e5.3) 4.30 (3.2e5.4) 0.980
IL-10 (pg/ml) 0.16 (0e1) 0.14 (0e1.1) 0.350
Charlson index 2.0 (1e2) 2.0 (1e2) 0.667
6 MWD
Distance (meters) 452 (84) 423 (82) 0.008
SpO2 fell >4%, n (%) 22 (32) 33 (31) 0.590
Dyspnea at final (Borg scale) 3.3 (2.7) 3.5 (2.6) 0.598
Legs fatigue at final (Borg scale) 2.7 (2.7) 2.8 (2.8) 0.109
Cycle-ergometer incremental exercise (n) 96 63
Workload peak (watts) 74 (26) 84 (27) 0.033
VO2 peak (L/min) 1.1 (0.3) 1.3 (0.3) <0.001
VO2 peak (% predicted) 61 (17) 59 (20) 0.528
VE peak (L/min) 42 (12) 48 (13) 0.101
VE peak/MVV 28 (9) 25 (6) 0.012
Heart rate peak (beats/min) 123 (19) 122 (22) 0.899
O2 pulse peak (ml/beat) 9.2 (2.9) 11.1 (2.5) <0.001
Lactate at final (mEq/L) 4.9 (2.3) 4.9 (1.7) 0.967
Dyspnea at final (Borg scale) 5.0 (2.8) 5.6 (2.5) 0.981
Legs fatigue at final (Borg scale) 4.7 (2.8) 5.0 (2.8) 0.046
Values are mean  SD, median (P25eP75) or number (%).
Definition of abbreviation: COPDNZ BMI < 30 and normal FFMI; COPDOZ Obese; COPDLZ low FFMI; FEV1Z forced expiratory volume in
one second; DLCOZ diffusing lung capacity; MMRCZ Modified Medical Research Council; HADZ hospital anxiety and depression scale;
MIPZ maximal inspiratory pressure; MEPZ maximal expiratory pressure VO2Z oxygen uptake; VEZ minute ventilation; 6MWDZ six-
minute walking distance; CRP Z C-reactive protein; TNFa Z tumor necrosis factor alpha.
a Chi-square tests and unpaired t-tests or Mann-Whitney U-tests significant between groups.
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higher ventilatory requirements at peak cycling exercise
compared to those with normal body mass composition;
and, (4) the two exercise protocols, 6MWT and CPET, also
showed differences in the type of determinants, namely:
anxietyedepression, daily physical activity and arterial
oxygenation played a significant role on exercise capacity
(6MWD) in non-obese COPD patients, but not on VO2
peak.Analysis of determinants of 6MWD and VO2 peak
The 6MWT is increasingly recognized as an important test
for clinical assessment and monitoring of COPD patients
[32]. We found that in COPDN, 6MWD showed an inverse
association with age together with a positive association
with PaO2. These observations are consistent with known
physiological determinants of exercise capacity [9]. Like-
wise, the significant association of daily physical activity
Table 2 Multivariate regression analyses using 6-min walking distance and VO2 peak as outcomes, according to obesity status.
6-min walking distance (m) VO2 peak (ml/min)
COPDN COPDO COPDN COPDO
Age (yrs) 4.0 (5.5 to 2.6)* 4.0
(5.6 to 2.4)*
17.6
(26.8 to 8.3)*
8.9
(16.8 to 1.1)z
Physical activities  3000 kcal/week 43.0 (16.0e70.1)z - - -
Dyspnea (mMRC scale, 0e4) 13.9 (22.9 to 4.9)y 23.4
(33.6 to 13.2)*
- 111.9
(159.8 to 64.0)*
Depression (HAD scale, 0e21) 4.6 (8.9 to 0.4) - - -
PaO2 (mmHg) 1.8 (0.8e2.8)
y - - -
FEV1 (% predicted) - - 5.9
(1.8e9.9)*
-
DLCO (% predicted) - - 8.2
(4.6e11.8)*
4.8 (1.4e8.3)z
BMI (kg/m2) - 6.0
(10.8 to 1.3)z
- -
Adjusted r2 0.35 0.37 0.31 0.47
Each column is a single multivariate model built with variables that show any value in the corresponding cell; variables not included in
the model are indicated as “-”. The magnitude of the association between each covariate and the outcome is expressed by the ß-value
and its 95% confidence interval, and interpreted as the variation in meters or ml/min for a unit of continuous covariates, and for the
change in category for FFMI, sex and physical activity.
Definition of abbreviations: 6MWD Z six-minute walking distance; VO2 peak Z oxygen uptake at peak exercise; MMRC Z Modified
Medical Research Council; HAD Z hospital anxiety and depression; FEV1 Z forced expiratory volume in one second; DLCO Z diffusing
lung capacity; BMI Z body mass index.
*p < 0.001; yp < 0.01; zp < 0.05.
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ietyedepression score confirm previous data [31,33]. By
contrast, our study provides novel data with respect to
the effects of body composition on 6MWD in COPD patients.
We observed that, the regression equation for 6MWD is
different between COPDO and COPDN. In the former,
COPDO, the equation includes a negative association with
BMI indicating that increased BMI determines a higher work
rate during the test that leads to lower walking speed and
lower distance [18,34]. As mentioned above, obese COPD
patients show an increase in the weight of the dyspnea
score as compared to COPDN [21,35].
Common determinants of VO2 peak in the two regression
models were the negative association with age and MMRC
and the positive weight of lung function measurements. It is
of note, however, that in COPDO (Table 2, last column),
dyspnea score emerged as the major covariate of VO2 peak,
due to higher ventilatory requirements at a given work rate
[17,18] compared to COPD patients with normal body mass
composition. But, recent studies seem to challenge that
constraints in respiratory mechanics due to obesity signifi-
cantly contribute to increased dyspnea during exercise
[17,36].
The current study indicates that the determinants of
exercise performance vary with the type of protocol, either
constant load sub-maximal exercise (6MWT) or incremental
exercise (VO2 peak) [13], but we confirmed the strong
relationship between dyspnea score and exercise perfor-
mance in COPDO patients, independently to the exercise
protocol.
It is of note that VO2 peakwas similar between COPDO and
COPDN, expressed either in absolute terms or as % predicted
(Table 1). In this line, several studies demonstrated thatmild to moderate obesity does not alter exercise perfor-
mance measured by endurance and/or incremental exercise
testing on cycle-ergometer [36]. In the current study, COPDO
patients have shown significantly higher IC/TLC values than
COPDN patients indicating their potential advantage to
perform exercise from a mechanical standpoint [21]. How-
ever, studies comparing treadmill and cycling exercise are
needed to determine if putative mechanical advantages of
obesity during cycling exercise are also evident during
weight-bearing exercise and to better elucidate the com-
plex and multifactorial nature of dyspnea in obese COPD
patients [36].
Exercise capacity and systemic inflammation
Low-grade chronic systemic inflammation has been observed
in different chronic diseases, including COPD and ageing
[37]. The current study, however, did not show consistent
relationships between exercise capacity and systemic
inflammation, consistent with previous reports [38]. How-
ever, the complexities of the interplay between COPD and
their co-morbidities [39] indicate the need for further lon-
gitudinal and integrative research in this field [40].
Strengths and limitations
The analysis of a large cohort of clinically stable patients
(nZ 251) recruited after the first hospital admission due to
an exacerbation of COPD is a unique feature of the current
research because it provides a picture of exercise perfor-
mance and its determinants at a very specific and important
time point during the natural course of the disease. Yet, our
750 D.A. Rodrı´guez et al.study has some limitations that deserve comment. Although
peripheral muscle strength was not an important determi-
nant, in our study it was only assessed by handgrip strength.
Quadriceps strength might have provided different results.
It is of note that 6MWD and VO2 peak could not be
determined in all patients, but we demonstrated that this
does not constraint our conclusions. Finally, we acknowl-
edge that our cross-sectional report cannot generate
prognostic information on longitudinal changes of exercise
capacity as disease progresses.
Conclusions and future perspectives
Taken together the findings of the study indicate that dys-
pnea is a significant limiting factor of exercise in obese COPD
patients independently of the degree of airflow limitation
and co-morbidities. Obesity has a relevant role limiting
6MWD and, consequently, it may have an impact on daily
physical activities [41]. Future COPD strategies should
include reduction of obesity as a key therapeutic objective
[18,42]. Moreover, the results highlight an independent as-
sociation of lung function and body composition on exercise
capacity in these patients indicating that body composition
shall be taken into account in the clinical interpretation of
exercise testing in COPD patients.
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